Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today ...

Dr Tomás Dias, Mursla Bio’s CSO, presented data from the study at one of the largest medical conferences, AASLD’s (American ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the ...

CAMBRIDGE, England & BOSTON, November 18, 2024--(BUSINESS WIRE)--Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

Mursla Bio has revealed outcomes from the MEV01 clinical study of its ‘EvoLiver’ blood test for the surveillance of hepatocellular carcinoma (HCC), primary liver cancer in high-risk cirrhotic ...

Selected to support scaling and commercialization strategy for extracellular vesicle-based disease surveillance and ...

Consortium funded by Horizon Europe, the largest European research and innovation program CAMBRIDGE, England & BOSTON, November 12, 2024--(BUSINESS WIRE)--Mursla Bio, a leader in Extracellular Vesicle ...